Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...
Travere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...
Medscape6d
Acute Postoperative Pain Management in the Older Patient
Aging Health. 2011;7(6):813-828. Common opioid side effects reported in the literature include urinary retention, pruritus, nausea and vomiting, CNS effects and respiratory effects. The incidence ...
BusinessMirror6d
paper waste in the philippines 2024
FILIPINO companies have contributed more investments in the country compared to foreign companies in the January to November 2024 period due to strong interest from investible funds, according to the ...